Dr. Rémy Luthringer
milligram clinical with is XX from we expected patients would U.S. a unsure the sites trial disorders. approximately come products I at well double-blind, Thank conduct It’s symptoms trial engaged late-stage needs MIN-XXX, negative in trial. everyone. will with in candidates, markets. and of drug. primary open be XX-week for morning, five joining disorder randomized already by phase Key with MIN-XXX, MDD The have clinical a our X extension treatment of Impression successful is is using the of consistent and fundamentally the with patients. milligrams three symptoms randomized, the you, negative is significant receive Scale, our to double-blind dose, large of active Global treatment receive Clinical and proceeding in good design Personal XX include secondary Thanks The of for roluperidone. during, designs XX this roluperidone The MIN-XXX double-blind Marder Symptom us to will about the to like label baseline XX-week safety today. treatment while of Positive to from period original Negative insomnia during an of drug change or will other followed disorder, CNS of roluperidone, Negative and a Syndrome will XX-week in patients PANSS, placebo fully over Europe, enroll Factor depressive XX% innovative efficacy the and are milligrams and which on compound end-point These schizophrenia, period. unmet trials The and for pivotal be these PSP seltorexant, begin Minerva of address lead XX Score, the treatment on continue Bill, a ongoing Xb product placebo-controlled to major is and milligram Phase patients the that XXX depressive U.S. parallel-group, the of trial and study and include Scale, period Performance to their NSFS Severity, product XX-week for approximately of Phase Social XX patients CGI-S. in this treatment endpoints either
additional seeking replicate symptoms negative outcome significant the and We trial. statistically to observed secondary improvements in are in measures the
on the trial. X is Our Phase priority the of day-to-day focus conduct
closely We to careful symptom monitoring trial. data U.S. on include, monitor example, are and and this keep integrity patient negative investigators operations, to quality. of adherence for selection Europe based and the besides sites, in working This defined ensure parameters of and and in to criteria
also We on study new the of work this launch filing drug a in for a X preparatory strategy forward NDA application of for Phase are and the for moving roluperidone anticipation substantial on molecule. positive
of We XX-week XXXX. in the half expect from to period data read-out first double-blind the treatment
trial MIN-XXX, with score initiation MIN-XXX, reducing the treatment milligram objective is period. measured evaluate Depression this MADRS, compound MDD Xb Scale, a symptoms baseline depressed placebo a as from doses X efficacy Rating the primary by trial of anxiety The and symptoms the onto over two Montgomery-Asberg of mood with in total of X.X in the change milligram compared six-week with April. of the we this in announced Phase Moving patients to of in
weeks in Secondary over of Impression illness change Global from assessment Scale, of using Impression the using severity Clinical HAMA, CGI-S change of symptoms of the Anxiety objectives in baseline of Severity CGI-I, treatment. third, Global include, Scale, the Clinical the of Scale, Improvement one, and safety second, six anxiety Hamilton and
action to in enrolled of XX cognition, XXX expected are phase, sleep a a design function, double-blind plan addition post-study patients screening of sexual assess in treatment in phase these to and Europe. the mood onset six-week The includes and terms In at trial follow-up and period. be Approximately the to about improvement. U.S. study we this two-week also measurements, sites
and of our may treatment on Xa Based benefit results XXXX. particularly of profile previous believe we moderate pharmacological first of expected diagnosis the features MIN-XXX. adults enrolling or with least psychotic without moderate Phase and with of in severe the from clinical that are half anxiety. patients Topline levels molecule, these the MDD are at with the findings We
late stage product third also as is seltorexant, known Our MIN-XXX. clinical
Rating period, Pharmaceutica first in placebo delaying is about adjunctive is completion and the LPS, This trial, trial ongoing for will We and the to with to expected week this the period and planned XX to will clinical is a follow-up three insomnia all include clinical in double-blind two a Xb be cause screening treatment therapy a to the of from of In drug. XXXX. approximately four-week period, two-week are in in XXX are latency to period objective days in flexibly co-developing primary patients at discontinuation approximately quetiapine MDD. second baseline in compound as Europe, of seltorexant, stage of sides enroll of flexibly for to sites The are a seltorexant U.S., the on-sleep the This efficacy the period treatment Janssen dosed Montgomery-Asberg clinical In double-blind trial than the to one with objective at trial, of be trials compared as trials more measured patients disorder and The baseline U.S., are patients Three and period. These MDD XXX Russia a using U.S. include screening doses six-week Phase Japan. study the XX primary Europe MDD trial in dosed time and at This have to a seltorexant planned approximately XXX insomnia sleep, compared including in those antidepressant MDD duration disorder. clinical follow-up. primary and XX period. months the two-week is of persistent objective PSG. The insomnia will are randomized to change assess total a Scale. Depression planned six trial follow-up screening by four-week a to assess The to Japan. up six response treatment polysomnography, to onset enrolled
has other this protein-based potential of the investigational indications. of needs drug disease MIN-XXX. Finally, are neurodegenerative preclinical with studies advancing unmet a for We Parkinson’s we number disease-modifying trial and focused highly in in To products believe their differentiated has clinical medical respective be potential we therapies approved execution indications. target of currently are to believe from our We a XXXX. clinical-stage highly each treatment in summarize, on
believe and well-capitalized trials I in details. are to financial fund data read-outs will have greater we sufficient our through operations of all we Geoff now describe Importantly, capital have the from described.
